BPA
DFTX

Beacon Pointe Advisors’s Definium Therapeutics DFTX Stock Holding History

Beacon Pointe Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,104
Closed -$18K – 1166
2022
Q1 		$18K Buy
+1,104
New +$19.2K ﹤0.01% 1181

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Beacon Pointe Advisors's DFTX Position: Q2 2022 in Review

Beacon Pointe Advisors sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 1,104 shares — an estimated $18K sold.

Beacon Pointe Advisors first reported a position in DFTX in Q1 2022 and held it in 1 quarter. The position peaked at $18K in Q1 2022. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Beacon Pointe Advisors reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Beacon Pointe Advisors sold 1,104 Definium Therapeutics shares in Q2 2022, an estimated $18K.
  • Beacon Pointe Advisors first reported a position in Definium Therapeutics in Q1 2022 and held it in 1 quarter.
  • Beacon Pointe Advisors's Definium Therapeutics position peaked at $18K in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Beacon Pointe Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.